Trifluorouracil Tepidopyrimidine
Targeted Therapy
Sun Yat-sen UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Targeted Therapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Sun Yat-sen University | Phase 2 | B |
Irinotecan Sun Yat-sen University | Phase 2 | B |
Epirubicin Peking University First Hospital | Phase 2 | CCC |
Axitinib Peking University First Hospital | Phase 2 | CCC |
Catequentinib Lei Li | Phase 2 | CCC |
View all 18 →
Same molecule, other indications
Trifluorouracil Tepidopyrimidine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →